Pharmaceutical

Intercept Pharmaceuticals (Nasdaq:ICPT) a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the REVERSE trial (Randomized Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis). As quoted in the press release: “NASH is poised to soon …

Intercept Pharmaceuticals (Nasdaq:ICPT) a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the REVERSE trial (Randomized Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis).

As quoted in the press release:

“NASH is poised to soon eclipse hepatitis C as the leading reason for liver transplants in the U.S. and Europe, so there is an urgent need for effective therapies that can reverse fibrosis and cirrhosis,” said Mark Pruzanski, M.D., President and CEO of Intercept. “OCA is currently the only FDA-designated Breakthrough Therapy in development for NASH and, with our Phase 3 trials REGENERATE and REVERSE underway, we are on track to bring the first approved therapy to NASH patients with fibrosis and cirrhosis who are at greatest risk of liver failure.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20491.01+284.60
TSXV712.49+11.95
DOW32654.59+431.17
S&P 5004088.85+80.84
NASD11984.52+321.73
ASX7093.00+17.90

COMMODITIES

Commodities
Gold1814.84-12.42
Silver21.63+0.03
Copper4.230.00
Palladium2061.00+51.00
Platinum954.00+9.00
Oil114.10+1.70
Heating Oil3.72+0.03
Natural Gas8.35+0.05

DOWNLOAD FREE REPORTS

×